Resilient Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Resilient Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).

17 total trials none currently recruiting 14 completed early-phase tilt top decile by trial count

Resilient Pharmaceuticals: 17 sponsored US clinical trials, none currently recruiting.

Resilient Pharmaceuticals sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 2 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage).

Top-decile sponsor footprint

Resilient Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 73/100

14 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

17 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

Study of Midomafetamine in Healthy Adults

NCT07584720

NOT YET RECRUITING Phase 1

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

NCT03606538

COMPLETED Phase 1

Food Effects on Bioavailability of MDMA in Healthy Volunteers

NCT05147402

TERMINATED Phase 2

Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD

NCT04784143

COMPLETED Phase 3

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

NCT04714359

COMPLETED

Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD

NCT05066282

COMPLETED Phase 3

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

NCT04077437

COMPLETED Phase 1

Evaluation of MDMA on Startle Response

NCT03181763

COMPLETED Phase 1

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

NCT02876172

COMPLETED

Correlates of Anxiety Associated With a Life-threatening Illness

NCT02954562

COMPLETED Phase 2

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

NCT02427568

COMPLETED Phase 2

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

NCT02008396

COMPLETED

Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD

NCT02102802

COMPLETED Phase 2

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610

COMPLETED Phase 1

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

NCT01404754

COMPLETED Phase 2

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

NCT01458327

COMPLETED Phase 2

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

NCT01211405

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 6
Phase 3 2

How the Resilient Pharmaceuticals early-phase archive is shaped

17 indexed studies, none listed as recruiting (0% open); 14 completed (82%).

Phase mix: 2 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Therapeutic area indexing for this sponsor is limited in the public registry.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Resilient Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Resilient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%5%10%15%20%25% Total trials Recruiting share Resilient PharmaceuticalsAchieve Life SciencesBioDelivery Sciences InternationalChugai PharmaceuticalConvaTec10xBio22nd Century Group23andMe3-C Institute for Social Development
Resilient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Resilient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 17 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Resilient Pharmaceuticals page

17 registered trials is a research-attention snapshot, not an endorsement of Resilient Pharmaceuticals or any single study.

  • None of Resilient Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Resilient Pharmaceuticals pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.